Randomized, controlled trial of telcagepant over four migraine attacks

Cephalalgia

Volumn 30, Issue 12, 2010, Pages 1443-1457

  Ho, Andrew P ^a   Dahlöf, Carl G H ^b   Silberstein, Stephen D ^c   Saper, Joel R ^d   Ashina, Messoud ^e   Kost, James T ^a   Froman, Samar ^a   Leibensperger, Heather ^a   Lines, Christopher R ^a   Ho, Tony W ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Gothenburg Migraine Clinic   (Sweden)

^c THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

^d Michigan Head Pain and Neurological Institute   (United States)

^e GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Calcitonin gene related peptide; Consistency; Migraine; Randomized controlled trial; Telcagepant

Indexed keywords

PLACEBO; TELCAGEPANT; ANALGESIC AGENT; AZEPINE DERIVATIVE; IMIDAZOLE DERIVATIVE; N (6 (2,3 DIFLUOROPHENYL) 2 OXO 1 (2,2,2 TRIFLUOROETHYL)AZEPAN 3 YL) 4 (2 OXO 2,3 DIHYDRO 1H IMIDAZO(4,5 B)PYRIDIN 1 YL)PIPERIDINE 1 CARBOXAMIDE; N-(6-(2,3-DIFLUOROPHENYL)-2-OXO-1-(2,2,2-TRIFLUOROETHYL)AZEPAN-3-YL)-4-(2-OXO-2, 3-DIHYDRO-1H-IMIDAZO(4,5-B)PYRIDIN-1-YL)PIPERIDINE-1-CARBOXAMIDE;

ABNORMAL LABORATORY RESULT; ADULT; ANALGESIA; ARTICLE; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DIARRHEA; DISEASE ACTIVITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEART PALPITATION; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MIGRAINE; MULTICENTER STUDY; NAUSEA; PAIN ASSESSMENT; PHONOPHOBIA; PHOTOPHOBIA; PNEUMONIA; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SOMNOLENCE; THORAX PAIN; UNSTABLE ANGINA PECTORIS; UPPER ABDOMINAL PAIN; VOMITING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL;

ADULT; ANALGESICS; AZEPINES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMIDAZOLES; MALE; MIGRAINE DISORDERS;

EID: 78650001597     PISSN: 03331024     EISSN: 14682982     Source Type: Journal    
DOI: 10.1177/0333102410370878     Document Type: Article

References (22)

1. Goadsby PJ, Edvinsson L, Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine attacks. Ann Neurol 1990; 28: 183-187. (Pubitemid 20244522)
2. Lassen LH, Haderslev PA, Jacobsen VB, Iversen HK, Sperling B, Olesen J. CGRP may play a causative role in migraine. Cephalalgia 2002; 22: 54-61. (Pubitemid 34626025)
3. Edvinsson L. New therapeutic target in primary head-aches: blocking the CGRP receptor. Expert Opin Ther Targets 2003; 7: 377-383. (Pubitemid 36722222)
4. Arulmani U, MaassenVanDenBrink A, Villalon CM, Saxena PR. Calcitonin gene-related peptide and its role in migraine pathophysiology. Eur J Pharm 2004; 500: 315-330. (Pubitemid 39304018)
5. Dahlof C, Deiner H-C. Migraine: an endemic disease inside the blood-brain barrier. Future Neurol 2009; 4: 405-420.
6. Olesen J, Diener HC, Husstedt IW, et al. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Eng J Med 2004; 350: 1104-1110. (Pubitemid 38298990)
7. Ho TW, Mannix LK, Fan X, et al. Randomized con-trolled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment ofmigraine. Neurology 2008; 70: 1304-1312. (Pubitemid 351550355)
8. Ho TW, Ferrari MD, Dodick DW, et al. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antag-onist of calcitonin gene-related peptide receptor, com-pared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial. Lancet 2008; 372: 2115-2123.
9. Connor KM, Shapiro RE, Diener H-C, et al. Rando-mized, controlled trial of telcagepant for the acute treat-ment ofmigraine. Neurology 2009; 73: 970-977.
10. Petersen KA, Birk S, Lassen LH, Kruuse C, Jonassen O, Lesko L, Olesen J. The CGRP-antagonist, BIBN4096BS does not affect cerebral or systemic haemodynamics in healthy volunteers. Cephalalgia 2005; 25: 139-147. (Pubitemid 40193957)
11. Dodick D, Lipton RB, Martin V, et al. Consensus state-ment: cardiovascular safety profile oftriptans (5-HT1B/1D agonists) in the acute treatment of migraine. Headache 2004; 44: 414-425. (Pubitemid 38685549)
12. Tfelt-Hansen P, Block G, Dahlof C, et al. Guidelines for controlled trials ofdrugs in migraine. 2nd ed. Cephalalgia 2000; 20: 765-786. (Pubitemid 32154559)
13. European Medicines Agency. Clinical Investigation of Medicinal Products for Treatment of Migraine. http://www.emea.europa.eu/htms/human/humanguidelines/ efficacy.htm. (Accessed 15 December 2009.)
14. International Headache Society. International Classifica-tion of Headache Disorders. 2nd ed. Cephalalgia 2004; 24(Suppl 1): 9-160.
15. Santanello NC, Hartmaier SL, Epstein RS, Silberstein SD. Validation of a new quality of life questionnaire for acute migraine headache. Headache 1995; 35: 330-337.
16. Atkinson MJ, Sinha A, Hass SL, et al. Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcomes 2004; 2: 12.
17. Marcus R, Peritz E, Gabriel KR. On closed testing pro-cedures with special reference to ordered analysis of var-iance. Biometrika 1976; 63: 655-660.
18. Lipton RB, Bigal ME, Stewart WF. Clinical trials of acute treatments for migraine including multiple attack studies of pain, disability, and health-related quality of life. Neurology 2005; 65(12 Suppl 4): 50-58.
19. Dahlof CG, Lipton RB, McCarroll KA, Kramer MS, Lines CR, Ferrari MD. Within-patient consistency of response of rizatriptan for treating migraine. Neurology 2000; 55: 1511-1516.
20. Kramer MS, Matzura-Wolfe D, Polis A, et al. A placebo-controlled crossover study of rizatriptan in the treatment ofmultiple migraine attacks. Rizatriptan Multiple Attack Study Group. Neurology 1998; 51: 773-781. (Pubitemid 28449258)
21. Merck & Co., Inc. Merck Announces First-Quarter 2009 Financial Results. Company Press Release, 21 April 2009. Available at: http://www.merck.com/newsroom/press-releases/financial/2009-0421.html (Last accessed 5 May 2010).
22. Brain SD, Williams TJ, Tippins JR, Morris HR, MacIntyre I. Calcitonin gene-related peptide is a potent vasodilator. Nature 1985; 13: 54-56. (Pubitemid 15192304)